Regulation of vascular tone by adipocytes

BMC Medicine

Volumn 9, Issue , 2011, Pages

  Maenhaut, Nele ^a   Van de Voorde, Johan ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPOCYTOKINE DERIVED RELAXING FACTOR; ADIPONECTIN; ANGIOTENSIN II; ANGIOTENSINOGEN; APELIN; HYDROGEN PEROXIDE; INTERLEUKIN 6; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OMENTIN; REACTIVE OXYGEN METABOLITE; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; BROWN ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; ENDOCRINE GLAND; ENDOTHELIAL DYSFUNCTION; FOAM CELL; HUMAN; HYPERTENSION; HYPOXIA; INFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; VASOCONSTRICTION; VASODILATATION; WHITE ADIPOSE TISSUE; ADIPOCYTE; METABOLISM; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

ADIPOCYTES; ADIPOKINES; HUMANS; MUSCLE, SMOOTH, VASCULAR;

EID: 79952709927     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-9-25     Document Type: Review

References (150)

1. Mariman EC, Wang P. Adipocyte extracellular matrix composition, dynamics and role in obesity. Cell Mol Life Sci 2010, 67:1277-1292. 10.1007/s00018-010-0263-4, 2839497, 20107860.
2. Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev 2004, 84:277-359. 10.1152/physrev.00015.2003, 14715917.
3. Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998, 22:1145-1158. 10.1038/sj.ijo.0800770, 9877249.
4. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004, 92:347-355. 10.1079/BJN20041213, 15469638.
5. Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 2009, 54:1847-1856. 10.1007/s10620-008-0585-3, 19052866.
6. Löhn M, Dubrovska G, Lauterbach B, Luft FC, Gollasch M, Sharma AM. Periadventitial fat releases a vascular relaxing factor. FASEB J 2002, 16:1057-1063.
7. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008, 29:2959-2971. 10.1093/eurheartj/ehn387, 18775919.
8. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM. PPARγ is required for placental, cardiac, and adipose tissue development. Mol Cell 1999, 4:585-595. 10.1016/S1097-2765(00)80209-9, 10549290.
9. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808. 296995, 14679176.
10. Curat CA, Miranville A, Sengenès C, Diehl M, Tonus C, Busse R, Bouloumié A. From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes 2004, 53:1285-1292. 10.2337/diabetes.53.5.1285, 15111498.
11. Gustafson B. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb 2010, 17:332-341.
12. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, Furukawa S, Tochino Y, Komuro R, Matsuda M, Shimomura I. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007, 56:901-911. 10.2337/db06-0911, 17395738.
13. Rausch ME, Weisberg S, Vardhana P, Tortoriello DV. Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. Int J Obes (Lond) 2008, 32:451-463. 10.1038/sj.ijo.0803744, 17895881.
14. Lolmède K, Durand de Saint Front V, Galitzky J, Lafontan M, Bouloumié A. Effects of hypoxia on the expression of proangiogenic factors in differentiated 3T3-F442A adipocytes. Int J Obes Relat Metab Disord 2003, 27:1187-1195.
15. Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch 2007, 455:479-492. 10.1007/s00424-007-0301-8, 2040175, 17609976.
16. Rutkowski JM, Davis KE, Scherer PE. Mechanisms of obesity and related pathologies: the macro- and microcirculation of adipose tissue. FEBS J 2009, 276:5738-5746. 10.1111/j.1742-4658.2009.07303.x, 2896500, 19754873.
17. Vona-Davis L, Rose DP. Angiogenesis, adipokines and breast cancer. Cytokine Growth Factor Rev 2009, 20:193-201. 10.1016/j.cytogfr.2009.05.007, 19520599.
18. Gao YJ, Takemori K, Su LY, An WS, Lu C, Sharma AM, Lee RM. Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion. Cardiovasc Res 2006, 71:363-373. 10.1016/j.cardiores.2006.03.013, 16756966.
19. Knock GA, Snetkov VA, Shaifta Y, Connolly M, Drndarski S, Noah A, Pourmahram GE, Becker S, Aaronson PI, Ward JP. Superoxide constricts rat pulmonary arteries via Rho-kinase-mediated Ca2+ sensitization. Free Radic Biol Med 2009, 46:633-642. 10.1016/j.freeradbiomed.2008.11.015, 19103285.
20. Ardanaz N, Pagano PJ. Hydrogen peroxide as a paracrine vascular mediator: regulation and signaling leading to dysfunction. Exp Biol Med (Maywood) 2006, 231:237-251.
21. Lucchesi PA, Belmadani S, Matrougui K. Hydrogen peroxide acts as both vasodilator and vasoconstrictor in the control of perfused mouse mesenteric resistance arteries. J Hypertens 2005, 23:571-579. 10.1097/01.hjh.0000160214.40855.79, 15716699.
22. Ketonen J, Shi J, Martonen E, Mervaala E. Periadventitial adipose tissue promotes endothelial dysfunction via oxidative stress in diet-induced obese C57Bl/6 mice. Circ J 2010, 74:1479-1487. 10.1253/circj.CJ-09-0661, 20526041.
23. Thengchaisri N, Kuo L. Hydrogen peroxide induces endothelium-dependent and -independent coronary arteriolar dilation: role of cyclooxygenase and potassium channels. Am J Physiol Heart Circ Physiol 2003, 285:H2255-H2263.
24. Gil-Longo J, González-Vázquez C. Characterization of four different effects elicited by H2O2 in rat aorta. Vascul Pharmacol 2005, 43:128-138. 10.1016/j.vph.2005.06.001, 15994130.
25. Gao YJ, Hirota S, Zhang DW, Janssen LJ, Lee RM. Mechanisms of hydrogen-peroxide-induced biphasic response in rat mesenteric artery. Br J Pharmacol 2003, 138:1085-1092. 10.1038/sj.bjp.0705147, 1573754, 12684264.
26. Marvar PJ, Hammer LW, Boegehold MA. Hydrogen peroxide-dependent arteriolar dilation in contracting muscle of rats fed normal and high salt diets. Microcirculation 2007, 14:779-791. 10.1080/10739680701444057, 17934963.
27. Moreno JM, Rodriguez Gomez I, Wangensteen R, Perez-Abud R, Duarte J, Osuna A, Vargas F. Mechanisms of hydrogen peroxide-induced vasoconstriction in the isolated perfused rat kidney. J Physiol Pharmacol 2010, 61:325-332.
28. Cooper D, Stokes KY, Tailor A, Granger DN. Oxidative stress promotes blood cell-endothelial cell interactions in the microcirculation. Cardiovasc Toxicol 2002, 2:165-180. 10.1007/s12012-002-0002-7, 12665663.
29. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986, 320:454-456. 10.1038/320454a0, 3007998.
30. Buyse M, Viengchareun S, Bado A, Lombès M. Insulin and glucocorticoids differentially regulate leptin transcription and secretion in brown adipocytes. FASEB J 2001, 15:1357-1366. 10.1096/fj.00-0669com, 11387233.
31. Frühbeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes 1999, 48:903-908.
32. Lembo G, Vecchione C, Fratta L, Marino G, Trimarco V, d'Amati G, Trimarco B. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes 2000, 49:293-297. 10.2337/diabetes.49.2.293, 10868946.
33. Vecchione C, Maffei A, Colella S, Aretini A, Poulet R, Frati G, Gentile MT, Fratta L, Trimarco V, Trimarco B, Lembo G. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes 2002, 51:168-173. 10.2337/diabetes.51.1.168, 11756337.
34. Matsuda K, Teragawa H, Fukuda Y, Nakagawa K, Higashi Y, Chayama K. Leptin causes nitric-oxide independent coronary artery vasodilation in humans. Hypertens Res 2003, 26:147-152. 10.1291/hypres.26.147, 12627874.
35. Kimura K, Tsuda K, Baba A, Kawabe T, Boh-oka S, Ibata M, Moriwaki C, Hano T, Nishio I. Involvement of nitric oxide in endothelium-dependent arterial relaxation by leptin. Biochem Biophys Res Commun 2000, 273:745-749. 10.1006/bbrc.2000.3005, 10873674.
36. Beltowski J. Role of leptin in blood pressure regulation and arterial hypertension. J Hypertens 2006, 24:789-801. 10.1097/01.hjh.0000222743.06584.66, 16612235.
37. Hercule HC, Schunck WH, Gross V, Seringer J, Leung FP, Weldon SM, da Costa Goncalves AC, Huang Y, Luft FC, Gollasch M. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler Thromb Vasc Biol 2009, 29:54-60. 10.1161/ATVBAHA.108.171298, 18927469.
38. Momin AU, Melikian N, Shah AM, Grieve DJ, Wheatcroft SB, John L, El Gamel A, Desai JB, Nelson T, Driver C, Sherwood RA, Kearney MT. Leptin is an endothelial-independent vasodilator in humans with coronary artery disease: evidence for tissue specificity of leptin resistance. European Heart Journal 2006, 27:2294-2299. 10.1093/eurheartj/ehi831, 16543250.
39. Fortuño A, Rodríguez A, Gómez-Ambrosi J, Muñiz P, Salvador J, Díez J, Frühbeck G. Leptin inhibits angiotensin II-induced intracellular calcium increase and vasoconstriction in the rat aorta. Endocrinology 2002, 143:3555-3560.
40. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006, 17:4-12.
41. Shankar A, Xiao J. Positive relationship between plasma leptin level and hypertension. Hypertension 2010, 56:623-628. 10.1161/HYPERTENSIONAHA.109.148213, 20713919.
42. Asferg C, Møgelvang R, Flyvbjerg A, Frystyk J, Jensen JS, Marott JL, Appleyard M, Jensen GB, Jeppesen J. Leptin, not adiponectin, predicts hypertension in the Copenhagen City Heart Study. Am J Hypertens 2010, 23:327-333. 10.1038/ajh.2009.244, 20019673.
43. Leung YM, Kwan CY. Dual vascular effects of leptin via endothelium: hypothesis and perspective. Chin J Physiol 2008, 51:1-6.
44. Quehenberger P, Exner M, Sunder-Plassmann R, Ruzicka K, Bieglmayer C, Endler G, Muellner C, Speiser W, Wagner O. Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res 2002, 90:711-718. 10.1161/01.RES.0000014226.74709.90, 11934840.
45. Juan CC, Chuang TY, Lien CC, Lin YJ, Huang SW, Kwok CF, Ho LT. Leptin increases endothelin type A receptor levels in vascular smooth muscle cells. Am J Physiol Endocrinol Metab 2008, 294:E481-E487. 10.1152/ajpendo.00103.2007, 18056787.
46. Korda M, Kubant R, Patton S, Malinski T. Leptin-induced endothelial dysfunction in obesity. Am J Physiol Heart Circ Physiol 2008, 295:H1514-H1521. 10.1152/ajpheart.00479.2008, 2593507, 18689498.
47. Zeidan A, Purdham DM, Rajapurohitam V, Javadov S, Chakrabarti S, Karmazyn M. Leptin induces vascular smooth muscle cell hypertrophy through angiotensin II- and endothelin-1-dependent mechanisms and mediates stretch-induced hypertrophy. J Pharmacol Exp Ther 2005, 315:1075-1084. 10.1124/jpet.105.091561, 16144973.
48. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, Klein AS, Bulkley GB, Bao C, Noble PW, Lane MD, Diehl AM. Leptin regulates proinflammatory immune responses. FASEB J 1998, 12:57-65.
49. Wagner EM. TNF-α induced bronchial vasoconstriction. Am J Physiol Heart Circ Physiol 2000, 279:H946-H951.
50. Zhang DX, Yi FX, Zou AP, Li PL. Role of ceramide in TNF-α-induced impairment of endothelium-dependent vasorelaxation in coronary arteries. Am J Physiol Heart Circ Physiol 2002, 283:H1785-H1794.
51. Baudry N, Vicaut E. Role of nitric oxide in effects of tumor necrosis factor-α on microcirculation in rat. J Appl Physiol 1993, 75:2392-2399.
52. Brian JE, Faraci FM. Tumor necrosis factor-α-induced dilatation of cerebral arterioles. Stroke 1998, 29:509-515.
53. Johns DG, Webb RC. TNF-α-induced endothelium-independent vasodilation: a role for phospholipase A2-dependent ceramide signaling. Am J Physiol 1998, 275:H1592-H1598.
54. Shibata M, Parfenova H, Zuckerman SL, Leffler CW. Tumor necrosis factor-α induces pial arteriolar dilation in newborn pigs. Brain Res Bull 1996, 39:241-247. 10.1016/0361-9230(95)02142-6, 8963690.
55. Thalmann S, Meier CA. Local adipose tissue depots as cardiovascular risk factors. Cardiovasc Res 2007, 75:690-701. 10.1016/j.cardiores.2007.03.008, 17412312.
56. Cheranov SY, Jaggar JH. TNF-α dilates cerebral arteries via NAD(P)H oxidase-dependent Ca2+ spark activation. Am J Physiol Cell Physiol 2006, 290:C964-C971. 10.1152/ajpcell.00499.2005, 1638900, 16267103.
57. Wort SJ, Ito M, Chou PC, Mc Master SK, Badiger R, Jazrawi E, de Souza P, Evans TW, Mitchell JA, Pinhu L, Ito K, Adcock IM. Synergistic induction of endothelin-1 by tumor necrosis factor α and interferon γ is due to enhanced NF-κB binding and histone acetylation at specific κB sites. J Biol Chem 2009, 284:24297-24305. 10.1074/jbc.M109.032524, 2782023, 19592490.
58. Brasier AR, Li J, Wimbish KA. Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator. Hypertension 1996, 27:1009-1017.
59. Greenstein AS, Khavandi K, Withers SB, Sonoyama K, Clancy O, Jeziorska M, Laing I, Yates AP, Pemberton PW, Malik RA, Heagerty AM. Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation 2009, 119:1661-1670. 10.1161/CIRCULATIONAHA.108.821181, 19289637.
60. Clément K, Viguerie N, Poitou C, Carette C, Pelloux V, Curat CA, Sicard A, Rome S, Benis A, Zucker JD, Vidal H, Laville M, Barsh GS, Basdevant A, Stich V, Cancello R, Langin D. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 2004, 18:1657-1669.
61. Zhang HR, Park YJ, Wu JX, Chen XP, Lee S, Yang J, Dellsperger KC, Zhang CH. Role of TNF-α in vascular dysfunction. Clin Sci 2009, 116:219-230. 10.1042/CS20080196, 2620341, 19118493.
62. Hector J, Schwarzloh B, Goehring J, Strate TG, Hess UF, Deuretzbacher G, Hansen-Algenstaedt N, Beil FU, Algenstaedt P. TNF-α alters visfatin and adiponectin levels in human fat. Horm Metab Res 2007, 39:250-255. 10.1055/s-2007-973075, 17447161.
63. Bulló M, García-Lorda P, Megias I, Salas-Salvadó J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 2003, 11:525-531.
64. Lee DL, Sturgis LC, Labazi H, Osborne JB, Fleming C, Pollock JS, Manhiani M, Imig JD, Brands MW. Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol 2006, 290:H935-H940. 10.1152/ajpheart.00708.2005, 16284237.
65. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767-1772.
66. Ohkawa F, Ikeda U, Kawasaki K, Kusano E, Igarashi M, Shimada K. Inhibitory effect of interleukin-6 on vascular smooth muscle contraction. Am J Physiol 1994, 266:H898-H902.
67. Minghini A, Britt LD, Hill MA. Interleukin-1 and interleukin-6 mediated skeletal muscle arteriolar vasodilation: in vitro versus in vivo studies. Shock 1998, 9:210-215. 10.1097/00024382-199803000-00009, 9525329.
68. Chudek J, Wiecek A. Adipose tissue, inflammation and endothelial dysfunction. Pharmacol Rep 2006, 58(Suppl):81-88.
69. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001, 60:329-339. 10.1079/PNS200194, 11681807.
70. Langenberg C, Bergstrom J, Scheidt-Nave C, Pfeilschifter J, Barrett-Connor E. Cardiovascular death and the metabolic syndrome: role of adiposity-signaling hormones and inflammatory markers. Diabetes Care 2006, 29:1363-1369. 10.2337/dc05-2385, 16732022.
71. Eringa EC, Bakker W, Smulders YM, Serné EH, Yudkin JS, Stehouwer CD. Regulation of vascular function and insulin sensitivity by adipose tissue: focus on perivascular adipose tissue. Microcirculation 2007, 14:389-402. 10.1080/10739680701303584, 17613810.
72. Schrader LI, Kinzenbaw DA, Johnson AW, Faraci FM, Didion SP. IL-6 deficiency protects against angiotensin II-induced endothelial dysfunction and hypertrophy. Arterioscler Thromb Vasc Biol 2007, 27:2576-2581. 10.1161/ATVBAHA.107.153080, 17962626.
73. Klouche M, Bhakdi S, Hemmes M, Rose-John S. Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J Immunol 1999, 163:4583-4589.
74. Charles CJ. Putative role for apelin in pressure/volume homeostasis and cardiovascular disease. Cardiovasc Hematol Agents Med Chem 2007, 5:1-10.
75. Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept 2005, 126:233-240. 10.1016/j.regpep.2004.10.019, 15664671.
76. Salcedo A, Garijo J, Monge L, Fernández N, García-Villalón AL, Sánchez Turrión V, Cuervas-Mons V, Diéguez G. Apelin effects in human splanchnic arteries: role of nitric oxide and prostanoids. Regul Pept 2007, 144:50-55. 10.1016/j.regpep.2007.06.005, 17628718.
77. Japp AG, Cruden NL, Amer DAB, Li VKY, Goudie EB, Johnston NR, Sharma S, Neilson I, Webb DJ, Megson IL, Flapan AD, Newby DE. Vascular effects of apelin in vivo in man. J Am Coll Cardiol 2008, 52:908-913. 10.1016/j.jacc.2008.06.013, 18772060.
78. Japp AG, Newby DE. The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. Biochem Pharmacol 2008, 75:1882-1892. 10.1016/j.bcp.2007.12.015, 18272138.
79. Kagiyama S, Fukuhara M, Matsumura K, Lin YZ, Fuji K, Iida M. Central and peripheral cardiovascular actions of apelin in conscious rats. Regul Pept 2005, 125:55-59. 10.1016/j.regpep.2004.07.033, 15582714.
80. Katugampola SD, Maguire JJ, Matthewson SR, Davenport AP. [125I]-(Pyr1)Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol 2001, 132:1255-1260. 10.1038/sj.bjp.0703939, 1572672, 11250876.
81. Kleinz MJ, Davenport AP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept 2004, 118:119-125. 10.1016/j.regpep.2003.11.002, 15003827.
82. Boucher J, Masri B, Daviaud D, Gesta S, Guigné C, Mazzucotelli A, Castan-Laurell I, Tack I, Knibiehler B, Carpéné C, Audigier Y, Saulnier-Blache JS, Valet P. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005, 146:1764-1771. 10.1210/en.2004-1427, 15677759.
83. Ashley EA, Powers J, Chen M, Kundu R, Finsterbach T, Caffarelli A, Deng A, Eichhorn J, Mahajan R, Agrawal R, Greve J, Robbins R, Patterson AJ, Bernstein D, Quertermous T. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res 2005, 65:73-82. 10.1016/j.cardiores.2004.08.018, 2517138, 15621035.
84. Higuchi K, Masaki T, Gotoh K, Chiba S, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice. Endocrinology 2007, 148:2690-2697. 10.1210/en.2006-1270, 17347313.
85. Chun HJ, Ali ZA, Kojima Y, Kundu RK, Sheikh AY, Agrawal R, Zheng LX, Leeper NJ, Pearl NE, Patterson AJ, Anderson JP, Tsao PS, Lenardo MJ, Ashley EA, Quertermous T. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 2008, 118:3343-3354. 2525695, 18769630.
86. Viengchareun S, Zennaro MC, Pascual-Le Tallec L, Lombes M. Brown adipocytes are novel sites of expression and regulation of adiponectin and resistin. FEBS Lett 2002, 532:345-350. 10.1016/S0014-5793(02)03697-9, 12482590.
87. Mallamaci F, Zoccali C, Cuzzola F, Tripepi G, Cutrupi S, Parlongo S, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y. Adiponectin in essential hypertension. J Nephrol 2002, 15:507-511.
88. Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C. Adiponectin: from obesity to cardiovascular disease. Obes Rev 2009, 10:269-279. 10.1111/j.1467-789X.2009.00571.x, 19389061.
89. Tan KC, Xu A, Chow WS, Lam MC, Ai VH, Tam SC, Lam KS. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 2004, 89:765-769. 10.1210/jc.2003-031012, 14764794.
90. Xi W, Satoh H, Kase H, Suzuki K, Hattori Y. Stimulated HSP90 binding to eNOS and activation of the PI3-Akt pathway contribute to globular adiponectin-induced NO production: vasorelaxation in response to globular adiponectin. Biochem Biophys Res Commun 2005, 332:200-205. 10.1016/j.bbrc.2005.04.111, 15896318.
91. Fésüs G, Dubrovska G, Gorzelniak K, Kluge R, Huang Y, Luft FC, Gollasch M. Adiponectin is a novel humoral vasodilator. Cardiovasc Res 2007, 75:719-727.
92. Gao YJ, Lu C, Su LY, Sharma AM, Lee RM. Modulation of vascular function by perivascular adipose tissue: the role of endothelium and hydrogen peroxide. Br J Pharmacol 2007, 151:323-331. 10.1038/sj.bjp.0707228, 2013985, 17384669.
93. Shatat IF, Freeman KD, Vuguin PM, Dimartino-Nardi JR, Flynn JT. Relationship between adiponectin and ambulatory blood pressure in obese adolescents. Pediatr Res 2009, 65:691-695. 10.1203/PDR.0b013e31819ea776, 19430383.
94. Lambert M, O'Loughlin J, Delvin EE, Levy E, Chiolero A, Paradis G. Association between insulin, leptin, adiponectin and blood pressure in youth. J Hypertens 2009, 27:1025-1032. 10.1097/HJH.0b013e32832935b6, 19293727.
95. Cao Y, Tao L, Yuan Y, Jiao X, Lau WB, Wang Y, Christopher T, Lopez B, Chan L, Goldstein B, Ma XL. Endothelial dysfunction in adiponectin deficiency and its mechanisms involved. J Mol Cell Cardiol 2009, 46:413-419. 10.1016/j.yjmcc.2008.10.014, 2671019, 19027750.
96. Shargorodsky M, Boaz M, Goldberg Y, Matas Z, Gavish D, Fux A, Wolfson N. Adiponectin and vascular properties in obese patients: is it a novel biomarker of early atherosclerosis?. Int J Obes (Lond) 2009, 33:553-558. 10.1038/ijo.2009.37, 19238157.
97. Chow WS, Cheung BMY, Tso AWK, Xu A, Wat NMS, Fong CHY, Ong LHY, Tam S, Tan KCB, Janus ED, Lam TH, Lam KSL. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 2007, 49:1455-1461. 10.1161/HYPERTENSIONAHA.107.086835, 17452504.
98. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003, 16:72-75. 10.1016/S0895-7061(02)03197-7, 12517687.
99. Ohashi K, Kihara S, Ouchi N, Kumada M, Fujita K, Hiuge A, Hibuse T, Ryo M, Nishizawa H, Maeda N, Maeda K, Shibata R, Walsh K, Funahashi T, Shimomura I. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006, 47:1108-1116. 10.1161/01.HYP.0000222368.43759.a1, 16651465.
100. Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun 2010, 393:668-672. 10.1016/j.bbrc.2010.02.053, 20170632.
101. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, Fried SK, Gong DW, Shuldiner AR, Pollin TI, McLenithan JC. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007, 56:1655-1661. 10.2337/db06-1506, 17329619.
102. Cai RC, Wei L, DI JZ, Yu HY, Bao YQ, Jia WP. Expression of omentin in adipose tissues in obese and type 2 diabetic patients. Zhonghua Yi Xue Za Zhi 2009, 89:381-384.
103. Moreno-Navarrete JM, Catalán V, Ortega F, Gómez-Ambrosi J, Ricart W, Frühbeck G, Fernández-Real JM. Circulating omentin concentration increases after weight loss. Nutr Metab (Lond) 2010, 7:27. 10.1186/1743-7075-7-27, 2859768, 20380714.
104. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008, 78:356-365. 10.1093/cvr/cvm111, 18093986.
105. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, Rossato M, Federspil G, Vettor R. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006, 91:3165-3170. 10.1210/jc.2006-0361, 16720654.
106. Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res 2009, 81:370-380. 10.1093/cvr/cvn288, 18952695.
107. Yamawaki H, Hara N, Okada M, Hara Y. Visfatin causes endothelium-dependent relaxation in isolated blood vessels. Biochem Biophys Res Commun 2009, 383:503-508. 10.1016/j.bbrc.2009.04.074, 19393628.
108. Saddi-Rosa P, Oliveira CS, Giuffrida FM, Reis AF. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr 2010, 2:21. 10.1186/1758-5996-2-21, 2857825, 20346149.
109. Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, Michelsen A, Damås JK, Tunheim SH, Ueland T, Smith C, Bendz B, Tonstad S, Gullestad L, Frøland SS, Krohg-Sørensen K, Russell D, Aukrust P, Halvorsen B. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007, 115:972-980. 10.1161/CIRCULATIONAHA.106.665893, 17283255.
110. Kim SR, Bae YH, Bae SK, Choi KS, Yoon KH, Koo TH, Jang HO, Yun I, Kim KW, Kwon YG, Yoo MA, Bae MK. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-κB activation in endothelial cells. Biochim Biophys Acta 2008, 1783:886-895. 10.1016/j.bbamcr.2008.01.004, 18241674.
111. Soltis EE, Cassis LA. Influence of perivascular adipose tissue on rat aortic smooth muscle responsiveness. Clin Exp Hypertens A 1991, 13:277-296. 10.3109/10641969109042063, 2065467.
112. Verlohren S, Dubrovska G, Tsang SY, Essin K, Luft FC, Huang Y, Gollasch M. Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries. Hypertension 2004, 44:271-276. 10.1161/01.HYP.0000140058.28994.ec, 15302842.
113. Takemori K, Gao YJ, Ding L, Lu C, Su LY, An WS, Vinson C, Lee RM. Elevated blood pressure in transgenic lipoatrophic mice and altered vascular function. Hypertension 2007, 49:365-372. 10.1161/01.HYP.0000255576.16089.b9, 17200435.
114. Gao YJ, Zeng ZH, Teoh K, Sharma AM, Abouzahr L, Cybulsky I, Lamy A, Semelhago L, Lee RM. Perivascular adipose tissue modulates vascular function in the human internal thoracic artery. J Thorac Cardiovasc Surg 2005, 130:1130-1136. 10.1016/j.jtcvs.2005.05.028, 16214530.
115. Schleifenbaum J, Köhn C, Voblova N, Dubrovska G, Zavarirskaya O, Gloe T, Crean CS, Luft FC, Huang Y, Schubert R, Gollasch M. Systemic peripheral artery relaxation by KCNQ channel openers and hydrogen sulfide. J Hypertens 2010, 28:1875-1882. 10.1097/HJH.0b013e32833c20d5, 20577128.
116. Yang L, Hu BR, Xiang JZ, Wang JL. Adventitium-derived relaxing factor may be a protein factor secreted by adipocytes with non-species-specificity and not limited to periadventitial fat. Chin J Pharmacol Toxicol 2005, 19:401-406.
117. Lee RM, Lu C, Su LY, Gao YJ. Endothelium-dependent relaxation factor released by perivascular adipose tissue. J Hypertens 2009, 27:782-790. 10.1097/HJH.0b013e328324ed86, 19516177.
118. Fang L, Zhao J, Chen Y, Ma T, Xu G, Tang C, Liu X, Geng B. Hydrogen sulfide derived from periadventitial adipose tissue is a vasodilator. J Hypertens 2009, 27:2174-2185. 10.1097/HJH.0b013e328330a900, 19644389.
119. Feng X, Chen Y, Zhao J, Tang C, Jiang Z, Geng B. Hydrogen sulfide from adipose tissue is a novel insulin resistance regulator. Biochem Biophys Res Commun 2009, 380:153-159. 10.1016/j.bbrc.2009.01.059, 19166813.
120. Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, Meng Q, Mustafa A, Mu W, Zhang S, Snyder SH, Wang R. H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine γ-lyase. Science 2008, 322:587-590. 10.1126/science.1162667, 2749494, 18948540.
121. Gálvez B, de Castro J, Herold D, Dubrovska G, Arribas S, González MC, Aranguez I, Luft FC, Ramos MP, Gollasch M, Fernández Alfonso MS. Perivascular adipose tissue and mesenteric vascular function in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 2006, 26:1297-1302.
122. Gao YJ, Holloway AC, Zeng ZH, Lim GE, Petrik JJ, Foster WG, Lee RM. Prenatal exposure to nicotine causes postnatal obesity and altered perivascular adipose tissue function. Obes Res 2005, 13:687-692. 10.1038/oby.2005.77, 15897477.
123. Maenhaut N, Boydens C, Van de Voorde J. Hypoxia enhances the relaxing influence of perivascular adipose tissue in isolated mice aorta. Eur J Pharmacol 2010, 641:207-212. 10.1016/j.ejphar.2010.05.058, 20553914.
124. Zhang CH, Hein TW, Wang W, Kuo L. Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res 2003, 92:322-329. 10.1161/01.RES.0000056759.53828.2C, 12595345.
125. Engeli S, Schling P, Gorzelniak K, Boschmann M, Janke J, Ailhaud G, Teboul M, Massiéra F, Sharma AM. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?. Int J Biochem Cell Biol 2003, 35:807-825. 10.1016/S1357-2725(02)00311-4, 12676168.
126. Lu H, Boustany-Kari CM, Daugherty A, Cassis LA. Angiotensin II increases adipose angiotensinogen expression. Am J Physiol Endocrinol Metab 2007, 292:E1280-E1287. 10.1152/ajpendo.00277.2006, 17213477.
127. Massiéra F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM, Quignard-Boulange A, Negrel R, Ailhaud G, Seydoux J, Meneton P, Teboul M. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001, 15:2727-2729.
128. Cai H, Li ZM, Dikalov S, Holland SM, Hwang JN, Jo H, Dudley SC, Harrison DG. NAD(P)H oxidase-derived hydrogen peroxide mediates endothelial nitric oxide production in response to angiotensin. J Biol Chem 2002, 277:48311-48317. 10.1074/jbc.M208884200, 12377764.
129. Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G. The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc Health Risk Manag 2008, 4:971-981. 2605336, 19183745.
130. Thatcher S, Yiannikouris F, Gupte M, Cassis L. The adipose renin-angiotensin system: role in cardiovascular disease. Mol Cell Endocrinol 2009, 302:111-117. 10.1016/j.mce.2009.01.019, 2748818, 19418627.
131. Das UN. Is angiotensin-II an endogenous pro-inflammatory molecule?. Med Sci Monit 2005, 11:RA155-RA162.
132. Ran J, Hirano T, Fukui T, Saito K, Kageyama H, Okada K, Adachi M. Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Metabolism 2006, 55:478-488. 10.1016/j.metabol.2005.10.009, 16546478.
133. Skurk T, van Harmelen V, Blum WF, Hauner H. Angiotensin II promotes leptin production in cultured human fat cells by an ERK1/2 dependent pathway. Obes Res 2005, 13:969-973. 10.1038/oby.2005.113, 15976138.
134. Oliver P, Picó C, Serra F, Palou A. Resistin expression in different adipose tissue depots during rat development. Mol Cell Biochem 2003, 252:397-400. 10.1023/A:1025500605884, 14577616.
135. Gentile MT, Vecchione C, Marino G, Aretini A, Di Pardo A, Antenucci G, Maffei A, Cifelli G, Iorio L, Landolfi A, Frati G, Lembo G. Resistin impairs insulin-evoked vasodilation. Diabetes 2008, 57:577-583. 10.2337/db07-0557, 18065520.
136. Dick GM, Katz PS, Farias M, Morris M, James J, Knudson JD, Tune JD. Resistin impairs endothelium-dependent dilation to bradykinin, but not acetylcholine, in the coronary circulation. Am J Physiol Heart Circ Physiol 2006, 291:H2997-H3002. 10.1152/ajpheart.01035.2005, 16905596.
137. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005, 111:932-939. 10.1161/01.CIR.0000155620.10387.43, 15710760.
138. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001, 409:307-312. 10.1038/35053000, 11201732.
139. Burnett MS, Devaney JM, Adenika RJ, Lindsay R, Howard BV. Cross-sectional associations of resistin, coronary heart disease, and insulin resistance. J Clin Endocrinol Metab 2006, 91:64-68. 10.1210/jc.2005-1653, 16249281.
140. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003, 88:4848-4856. 10.1210/jc.2003-030519, 14557464.
141. Sentinelli F, Romeo S, Arca M, Filippi E, Leonetti F, Banchieri M, Di Mario U, Baroni MG. Human resistin gene, obesity, and type 2 diabetes: mutation analysis and population study. Diabetes 2002, 51:860-862. 10.2337/diabetes.51.3.860, 11872692.
142. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med 2008, 14:741-751. 10.2119/2008-00058.Rabe, 2582855, 19009016.
143. Kougias P, Chai H, Lin PH, Lumsden AB, Yao QZ, Chen CY. Adipocyte-derived cytokine resistin causes endothelial dysfunction of porcine coronary arteries. J Vasc Surg 2005, 41:691-698. 10.1016/j.jvs.2004.12.046, 15874935.
144. Chen C, Jiang J, Lü JM, Chai H, Wang X, Lin PH, Yao Q. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 2010, 299:H193-H201. 10.1152/ajpheart.00431.2009, 20435848.
145. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, Mickle DA. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003, 108:736-740. 10.1161/01.CIR.0000084503.91330.49, 12874180.
146. Zhang L, Curhan GC, Forman JP. Plasma resistin levels associate with risk for hypertension among nondiabetic women. J Am Soc Nephrol 2010, 21:1185-1191. 10.1681/ASN.2009101053, 20378819.
147. Avram AS, Avram MM, James WD. Subcutaneous fat in normal and diseased states: 2. Anatomy and physiology of white and brown adipose tissue. J Am Acad Dermatol 2005, 53:671-683. 10.1016/j.jaad.2005.05.015, 16198791.
148. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo FC, Palmer EL, Tseng YH, Doria A, Kolodny GM, Kahn CR. Identification and importance of brown adipose tissue in adult humans. N Engl J Med 2009, 360:1509-1517. 10.1056/NEJMoa0810780, 2859951, 19357406.
149. Nedergaard J, Bengtsson T, Cannon B. Unexpected evidence for active brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab 2007, 293:E444-E452. 10.1152/ajpendo.00691.2006, 17473055.
150. Seale P, Lazar MA. Brown fat in humans: turning up the heat on obesity. Diabetes 2009, 58:1482-1484. 10.2337/db09-0622, 2699856, 19564460.